Evicenter
P&T meetings

Ulixacaltamide

Essential tremor

Regulatory submission
NDA submitted by February 2026
Launch
Not announced
Last updated
78 sources

Product information and disease descriptionProduct descriptionProduct information

Access and distribution

2 evidence topics · 2 sources

Anticipated distribution strategy

“May 7, 2026” (opens the source at this quote in a new tab)

“Distribution network is established, with commercial inventory build in-progress ahead of launch.” (opens the source at this quote in a new tab)

Expanded access policy

“Requests will be considered on a case-by-case basis.” (opens the source at this quote in a new tab)

“All requests must be submitted by the patient’s treating physician.” (opens the source at this quote in a new tab)

Anticipated patient support programs

No evidence found.